Two cases of catastrophic antiphospholipid syndrome

Lupus

Volumn 14, Issue 11, 2005, Pages 907-909

  Navarrete, Nuria ^a,b   Macias P ^a   Jaen F ^a   Hidalgo, C ^a   Caliz R ^a   Jimenez Alonso J ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^b NONE   (Spain)

Author keywords

Anticoagulation; Catastrophic antiphospholipid syndrome; Corticosteroids; Survival

Indexed keywords

CORTICOSTEROID; ENOXAPARIN; METHYLPREDNISOLONE; PIPERACILLIN PLUS TAZOBACTAM; PREDNISONE;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; CASE REPORT; CATASTROPHIC ANTIPHOSPHOLIPID SYNDROME; EARLY DIAGNOSIS; EVOLUTION; FEMALE; FOLLOW UP; HUMAN; INFECTION; PREGNANCY; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL; VASCULAR DISEASE;

ADULT; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; FEMALE; HUMANS; MULTIPLE ORGAN FAILURE; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

EID: 28444435508     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203305lu2167cr     Document Type: Article

References (16)

1. Wilson WA, Gharavi AE, Koike T et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an internacional workshop. Arthritis Rheum 1999; 42: 1309-1311.
2. Gómez-Puerta J, Gil V, Cervera R. "Catastrophic" antiphospholipid syndrome. Mayo Clinic Proceedings 2003; 78: 519.
3. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002; 346: 752-763.
4. Schaar CG, Ronday KH, Boets EP, van der Lubbe PA, Breedveld FC. Catastrophic manifestations of the antiphospholipid syndrome. J Rheumatol 1999; 26: 2261-2264.
5. Asherson RA, Piette JC. The catastrophic antiphospholipid syndrome 1996. Acute multi-organ failure associated with antiphospholipid antibodies: a review of 31 patients. Lupus 1996; 5: 414-417.
6. Asherson RA, Espinosa G, Cervera F, Font J, Reverter JC. Catastrophic antiphospholipid syndrome: proposed guidelines for diagnosis and treatment. J Clin Rheumatol 2002; 8: 157-165.
7. Asherson RA, Cervera R, Piette JC et al. Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients. Medicine 1998; 77: 195-207.
8. Asherson RA, Cervera R, de Groot PE et al. Catastrophic antiphospholipid sindrome: international consensus statement on classification criteria and treatment guidelines. Lupus 2003; 12: 530-534.
9. Khamastha MA, Cuadrado MJ, Mugic F et al. The management of thrombosis in the antiphospholipid antibody syndrome. N Engl J Med 1995; 332: 993-997.
10. Khamastha MA. The management of thrombosis and pregnancy loss in the antiphospholipid syndrome. Lupus 1998; 7: 162-165.
11. Schulman S, Svenungsson E, Granqvist S. Duration of Anticoagulation Study Group. Anticardiolipin antibodies predict early recurrence of thromboembolism and the death among patients with venous thromboembolism following anticoagulant therapy. Am J Med 1998; 104: 332-338.
12. Firshman P. Prevention of fetal loss in experimental antiphospholipid syndrome by in vivo administration of recombinant Interleukin 3. J Clin Invest 1993; 91: 1834-1837.
13. Blank M, George J, Fishman P. Ciprofioxacin immunomodulation of experimental antiphospholipid syndrome associated with elevation of Interleukin 3 and granulocyte macrophage colony stimulating factor expression. Arthritis Rheum 1998; 41: 224-222.
14. Blank M, Krouse Y. Bromocriptin immunomodulation of experimental SLE and primary antiphospholipid syndrome via induction of non-specific T supressors cells. Cell Immunol 1995; 162: 144-122.
15. Erkan D, Yazici Y, Sobel R, Lockshin MD. Primary antiphospholipid syndrome. Functional outcome after 10 years. Rheumatol 2000; 27: 2817-2821.
16. Ekan D, Asherson RA, Espinosa G et al. Long term outcome of catastrophic antiphospholipid syndrome survivors. Ann Rheum Dis 2003; 62: 530-533.